Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s share price reached a new 52-week low during trading on Wednesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 5000 shares traded. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Price Performance
The company has a debt-to-equity ratio of 138.88, a quick ratio of 0.46 and a current ratio of 0.07. The firm has a market cap of C$1.33 million, a P/E ratio of -1.00 and a beta of -0.02. The company has a 50-day moving average of C$0.01 and a 200 day moving average of C$0.02.
Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last posted its earnings results on Thursday, August 29th. The company reported C($0.01) EPS for the quarter. The company had revenue of C$0.16 million during the quarter. On average, sell-side analysts anticipate that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current year.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Articles
- Five stocks we like better than Aequus Pharmaceuticals
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- The Basics of Support and Resistance
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
